Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: A systematic review and economic evaluation

Health Technology Assessment

Volumn 16, Issue 17, 2012, Pages 1-265

  Sharma, P ^a   Boyers, D ^a,b   Boachie, C ^a   Stewart, F ^a   Miedzybrodzka, Z ^b   Simpson, W ^c   Kilonzo, M ^b   McNamee, P ^b   Mowatt, G ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c NHS GRAMPIAN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR;

APOB GENE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC KIT; ECONOMIC EVALUATION; FALSE POSITIVE RESULT; FAMILIAL HYPERCHOLESTEROLEMIA; GENE; GENE MUTATION; GENE SEQUENCE; GENETIC SCREENING; GENOTYPE; HUMAN; LDLR GENE; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; MUTATIONAL ANALYSIS; PCSK9 GENE; PROGNOSIS; QUALITY ADJUSTED LIFE YEAR; REVIEW; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; FEMALE; GENETIC TESTING; GREAT BRITAIN; HUMANS; HYPERCHOLESTEROLEMIA; INFANT; MALE; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; SENSITIVITY AND SPECIFICITY; TECHNOLOGY ASSESSMENT, BIOMEDICAL; YOUNG ADULT;

EID: 84863108353     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta16170     Document Type: Review

References (98)

1. National Institute for Health and Clinical Excellence. Identification and management of familial hypercholesterolaemia. CG71. London: National Institute for Health and Clinical Excellence; 2008. URL: www.nice.org.uk/nicemedia/live/12048/41700/41700.pdf (accessed April 2011).
2. Main L. Inherited heart conditions: familial hypercholesterolaemia. Heart UK and British Heart Foundation; 2011. URL: www.heartuk.org.uk/index.php?/healthy_living/inherited_ heart_conditions_-_familial_hypercholesterolaemia/ (accessed April 2011).
3. Bhatnagar D. Familial hypercholesterolaemia: the case for finding the patients and finding their genes. Preston: Cardiac and Stroke Networks Prevention and Detection Conference; 2009. URL: www.csnlc.nhs.uk/uploads/files/cardiac/events/internal/2009_prevent_and_ detection/Dr_Deepak_Bhatnagar_Familial_Hypercholesterolemia_the_case_for_finding_the_patients_and_finding_their_genes.pdf (accessed April 2011).
4. Bhatnagar D. Diagnosis and screening for familial hypercholesterolaemia: finding the patients, finding the genes. Ann Clin Biochem 2006;43:441-56.
5. Marks D, Thorogood M, Neil HAW, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 2003;168:1-14.
6. Western Australian Program Committee. Model of care: familial hypercholesterolaemia. Canberra: Government of Western Australia Department of Health; 2008. URL: www.healthnetworks.health.wa.gov.au/modelsofcare/docs/Familial%20Hyperch olesterolaemia%20Model%20of%20Care.pdf (accessed April 2011).
7. Connor M, Ferguson-Smith M. Essential medical genetics. 5th edn. Oxford: Blackwell; 1997.
8. Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DCG, Liem AH, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 2008;337:a2423.
9. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Scientific Steering Committee on behalf of the Simon Broome Register Group. Atherosclerosis 1999;142:105-12.
10. Department of Health (DoH). Familial hypercholesterolemia cascade testing project. Recommendations to the DoH from the Steering Group of the DH FH Cascade Testing Audit Project. London: Department of Health; 2007. URL: www.heartuk.org.uk/HealthProfessionals/index.php/fh_cascade_testing_proj ect/ (accessed April 2011).
11. Leren TP, Finborud TH, Manshaus TE, Ose L, Berge KE. Diagnosis of familial hypercholesterolemia in general practice using clinical diagnostic criteria or genetic testing as part of cascade genetic screening. Community Genet 2008;11:26-35.
12. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol 2004;160:407-20.
13. Centre for Cardiovascular Genetics, University College London. LDLR (low density lipoprotein receptor) database @ LOVD (Leiden Open Variation Database); 2011. URL: www.ucl.ac.uk/ldlr (accessed April 2011).
14. Leigh SE, Foster AH, Whittall RA, Hubbart CS, Humphries SE. Update and analysis of the University College London low density lipoprotein receptor familial hypercholesterolemia database. Ann Hum Genet 2008;72:4-98.
15. Varret M, Abifadel M, Rabes J-P, Boileau C. Genetic heterogeneity of autosomal dominant hypercholesterolemia. Clin Genet 2008;73:1-13.
16. Sijbrands EJ, Westendorp RG, Defesche JC, de Meier PH, Smelt AH, Kastelein JJ. Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study. BMJ 2001;322:1019-23.
17. Warner M. Child-parent screening for familial hypercholesterolaemia: screening strategy based on a meta-analysis. Ann Clin Biochem 2008;45:114.
18. Royal College of Physicians. The national audit of the management of familial hypercholesterolaemia 2010. London: Royal College of Physicians; 2010. URL: www.rcplondon.ac.uk/sites/default/files/fh-full-audit-report-2011.pdf (accessed April 2011).
19. Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ, Scheerder RL, Kastelein JJ. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet 2001;357:165-8.
20. Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ 1991;303:893-6.
21. Department of Primary Care Health Sciences, University of Oxford. Simon Broome FH register; 2011. URL: www.primarycare.ox.ac.uk/research/vascular/Research/simon_broome/ (accessed October 2011).
22. Kwiterovich PO Jr, Fredrickson DS, Levy RI. Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood. J Clin Invest 1974;53:1237-49.
23. Leonard JV, Whitelaw AG, Wolff OH. Diagnosing familial hypercholesterolaemia in childhood by measuring serum cholesterol. Br Med J 1977;1:1566-8.
24. Marks D, Wonderling D, Thorogood M, Lambert H, Humphries SE, Neil HA. Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis. Health Technol Assess 2000;4(29).
25. Humphries SE, Galton D, Nicholls P. Genetic testing for familial hypercholesterolaemia: practical and ethical issues. QJM 1997;90:169-81.
26. Humphries SE, Whittall RA, Hubbart CS, Maplebeck S, Cooper JA, Soutar AK, et al. Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J Med Genet 2006;43:943-9.
27. Heath KE, Humphries SE, Middleton-Price H, Boxer M. A molecular genetic service for diagnosing individuals with familial hypercholesterolaemia (FH) in the United Kingdom. Eur J Hum Genet 2001;9:244-52.
28. Taylor A, Martin B, Wang D, Patel K, Humphries SE, Norbury G. Multiplex ligationdependent probe amplification analysis to screen for deletions and duplications of the LDLR gene in patients with familial hypercholesterolaemia. Clin Genet 2009;76:69-75.
29. Department of Health. National service framework for children, young people and maternity services: core standard. London: Department of Health; 2007. URL: www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPoli cyAndGuidance/Browsable/DH_4094329 (accessed April 2011).
30. Marks D, Thorogood M, Farrer JM, Humphries SE. Census of clinics providing specialist lipid services in the United Kingdom. J Public Health 2004;26:353-4.
31. Department of Health. Primary care service framework: familial hypercholesterolaemia. London: Department of Health; 2010. URL: www.pcc.nhs.uk/uploads/commissioning/2010/02/primary_care_service_framew ork_familial_hypercholesterolaemia.pdf (accessed April 2011).
32. Goldberg AC, Hopkins PN, Toth PP, Ballantyne C, Rader DJ, Robinson JG, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011;5:133-40.
33. US Preventive Services Task Force. Screening for lipid disorders in children. Rockville, MD: US Preventive Services Task Force; 2007. URL: www.uspreventiveservicestaskforce.org/uspstf/uspschlip.htm (accessed April 2011).
34. Heart UK. Looking forward in lipids. Maidenhead: Heart UK; 2008. URL: www.heartuk.org.uk/artman/publish/article_615.shtml (accessed April 2011).
35. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003;3:1-13.
36. Hooper AJ, Nguyen LT, Burnett JR, Van Bockxmeer FM. Molecular screening approach for identification of mutations causing familial hypercholesterolaemia in Western Australia. Twin Res Hum Genet 2009;12:218.
37. Taylor A, Wang D, Patel K, Whittall R, Wood G, Farrer M, et al. Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project. Clin Genet 2010;77:572-80.
38. Yarram L. Familial hypercholesterolaemia: LIPOchip experience. Clinical Molecular Genetics Society meeting, St Catherine's College, Oxford, April 2010. URL: www.cmgs.org/Restricted%20access%20area/CMGS%20members/CMGS%202010/SP1_5 /SP01%20FH%20Lipochip%20experience%20CMGS.ppt (accessed April 2011).
39. Alonso R, Defesche JC, Tejedor D, Castillo S, Stef M, Mata N, et al. Genetic diagnosis of familial hypercholesterolemia using a DNA-array based platform. Clin Biochem 2009;42:899-903.
40. Callaway J, Wood O, Cross E, Skinner AC, Harvey JF. Validation of a novel mutation screening strategy for familial hypercholesterolaemia LIPOchip, a DNA-array based system. J Med Genet 2010;47:S62.
41. Palacios L, Stef M, Taylor A, Humphries SE, Cuevas N, McAnulty C, et al. Rapid and accurate genetic diagnosis by Lipochip (R) in UK FH patients. Atheroscler Suppl 2010;11:31.
42. Stef M, Palacios L, Tejedor D, Martinez A. The LIPOchip experience in Spain. Atheroscler Suppl 2009;10:e1001.
43. Tejedor D, Castillo S, Mozas P, Jimenez E, Lopez M, Tejedor MT, et al. Reliable low-density DNA array based on allele-specific probes for detection of 118 mutations causing familial hypercholesterolemia. Clin Chem 2005;51:1137-44.
44. Civeira F, Ros E, Jarauta E, Plana N, Zambon D, Puzo J, et al. Comparison of genetic versus clinical diagnosis in familial hypercholesterolemia. Am J Cardiol 2008;102:1187-93.
45. Damgaard D, Larsen ML, Nissen PH, Jensen JM, Jensen HK, Soerensen VR, et al. The relationship of molecular genetic to clinical diagnosis of familial hypercholesterolemia in a Danish population. Atherosclerosis 2005;180:155-60.
46. Mabuchi H, Higashikata T, Nohara A, Lu H, Yu WX, Nozue T, et al. Cutoff point separating affected and unaffected familial hypercholesterolemic patients validated by LDL-receptor gene mutants. J Atheroscler Thromb 2005;12:35-40.
47. Widhalm K, Dirisamer A, Lindemayr A, Kostner G. Diagnosis of families with familial hypercholesterolaemia and/or Apo B-100 defect by means of DNA analysis of LDL-receptor gene mutations. J Inherit Metab Dis 2007;30:239-47.
48. Lee WP, Ong BB, Haralambos K, Townsend D, Rees JAE, Williams EJ, et al. Familial hypercholesterolaemia screening - application of genetic testing and diagnostic LDL-C cut-off values for relatives of FH patients in a Welsh population. Eur Heart J Suppl 2010;12:F20-21.
49. Starr B, Hadfield SG, Hutten BA, Lansberg PJ, Leren TP, Damgaard D, et al. Development of sensitive and specific age- and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing. Clin Chem Lab Med 2008;46:791-803.
50. Wiegman A, Rodenburg J, de Jongh S, Defesche JC, Bakker HD, Kastelein JJP, et al. Family history and cardiovascular risk in familial hypercholesterolemia: data in more than 1000 children. Circulation 2003;107:1473-8.
51. Yu W, Nohara A, Higashikata T, Lu H, Inazu A, Mabuchi H. Molecular genetic analysis of familial hypercholesterolemia: spectrum and regional difference of LDL receptor gene mutations in Japanese population. Atherosclerosis 2002;165:335-42.
52. Stef M. Rapid diagnosis of familial hypercholesterolemia in British patients. New and developing technologies for genetic diagnostics. Salisbury, 5-6 July 2010. URL: www.ngrl.org.uk/Wessex/downloads/tm10/TM10-S2-2%20Marianne%20Stef.pdf (accessed March 2011).
53. Leren TP, Manshaus T, Skovholt U, Skodje T, Nossen IE, Teie C, et al. Application of molecular genetics for diagnosing familial hypercholesterolemia in Norway: results from a family-based screening program. Semin Vasc Med 2004;4:75-85.
54. Taylor A, Tabrah S, Wang D, Sozen M, Duxbury N, Whittall R, et al. Multiplex ARMS analysis to detect 13 common mutations in familial hypercholesterolaemia. Clin Genet 2007;71:561-8.
55. Tabrah S, Tabrah S, Taylor A, Humphries SE, Norbury G. A strategy for molecular genetic mutation screening for familial hypercholesterolaemia. J Med Genet 2005;42:S110.
56. Tejedor D, Castillo S, Mozas P, Jimenez E, Lopez M, Tejedor MT, et al. Comparison of DNA array platform vs DNA sequencing as genetic diagnosis tools for familial hypercholesterolemia. Clin Chem 2006;52:1971-2.
57. Oliva J, Lopez-Bastida J, Moreno SG, Mata P, Alonso R. Cost-effectiveness analysis of a genetic screening program in the close relatives of Spanish patients with familial hypercholesterolemia. Rev Esp Cardiol 2009;62:57-65.
58. Fouchier SW, Defesche JC, Umans-Eckenhausen MAW, Kastelein JJP. The molecular basis of familial hypercholesterolemia in the Netherlands. Hum Genet 2001;109:602-15.
59. Wonderling D, Umans-Eckenhausen MAW, Marks D, Defesche JC, Kastelein JJP, Thorogood M. Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in the Netherlands. Semin Vasc Med 2004;4:97-104.
60. Marang-van de Mheen PJ, Ten Asbroek AHA, Bonneux L, Bonsel GJ, Klazinga NS. Cost-effectiveness of a family and DNA based screening programme on familial hypercholesterolaemia in The Netherlands. Eur Heart J 2002;23:1922-30.
61. D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117:743-53.
62. Marks D, Wonderling D, Thorogood M, Lambert H, Humphries SE, Neil HAW. Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia. BMJ 2002;324:1303-6.
63. Marks D, Thorogood M, Neil AW, Wonderling D, Humphries SE. Comparing costs and benefits over a 10 year period of strategies for familial hypercholesterolaemia screening. J Public Health Med 2003;25:47-52.
64. Marks D, Wonderling D, Thorogood M, Lambert H, Humphries SE, Neil HAW. Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost effectiveness analysis. analysis. Health Technol Assess 2000;4(29).
65. Leren TP. Cascade genetic screening for familial hypercholesterolemia. Clin Genet 2004;66:483-7.
66. Humphries SE, Norbury G, Leigh S, Hadfield SG, Nair D. What is the clinical utility of DNA testing in patients with familial hypercholesterolaemia? Curr Opin Lipidol 2008;19:362-8.
67. Hadfield SG, Horara S, Starr BJ, Yazdgerdi S, Marks D, Bhatnagar D, et al. Family tracing to identify patients with familial hypercholesterolaemia: the second audit of the Department of Health Familial Hypercholesterolaemia Cascade Testing Project. Ann Clin Biochem 2009;46:24-32.
68. NICE. Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: final scope. London: National Institute for Health and Clinical Excellence; 2010. URL: http://guidance.nice.org.uk/DT/2/Scope/pdf/English (accessed April 2011).
69. Stockdale C, Yarram L, Williams M. Application of LIPOchip technology to genetic screening in autosomal dominant hypercholesterolaemia referrals. Association for Clinical Cytogenetics/ Clinical Molecular Genetics Society spring meeting, Durham, 2011. URL: www.springmeeting.cytogenetics.org.uk/posters%5CM7.chris.stockdale.pdf (accessed April 2011).
70. Hadfield SG, Horara S, Starr BJ, Yazdgerdi S, Bhatnagar D, Cramb R, et al. Are patients with familial hypercholesterolaemia well managed in lipid clinics? An audit of eleven clinics from the Department of Health Familial Hypercholesterolaemia Cascade Testing project. Ann Clin Biochem 2008;45:199-205.
71. NICE. Statins for the prevention of cardiovascular events. TA94. London: National Institute for Health and Clinical Excellence; 2006. URL: www.nice.org.uk/nicemedia/live/11564/33151/33151.pdf (accessed April 2011).
72. Department of Health. Health survey for England 1996. London: Department of Health; 1998. URL: www.archive.official-documents.co.uk/document/doh/survey96/ehtitle.htm (accessed April 2011).
73. Cole JA, Smith SM, Hart N, Cupples ME. Systematic review of the effect of diet and exercise lifestyle interventions in the secondary prevention of coronary heart disease. Cardiol Res Pract 2011;1: article no. 232351. DOI: 10.4061/2011/232351.
74. Department of Health. NHS payment by results 2010-11 national tariff information. London: Department of Health; 2011. URL: www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/@ps/documen ts/digitalasset/dh_113900.xls (accessed April 2011).
75. Curtis L. Unit costs of health and social care. Canterbury, Kent: Personal Social Services Research Unit, University of Kent; 2010. URL: www.pssru.ac.uk/uc/uc2010contents.htm (accessed April 2011).
76. British Medical Association and Royal Pharmaceutical Society of Great Britain. British national formulary. No. 61, 2011. London: BMA and RPS; 2011. URL: www.bnf.org/ (accessed April 2011).
77. Vuorio A, Kuoppala J, Kovanen PT, Humphries SE, Strandberg T, Tonstad S, et al. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev 2010; Issue 7, Art No. CD006401.
78. Briggs A. A Bayesian approach to stochastic cost-effectiveness analysis. Health Econ 1999;8:257-61.
79. Tennant S, Bell C, Brown C, Kelly K, Hailey H, Gregory H, et al. Familial hypercholesterolaemia testing in Scotland [poster presentation]. British Society for Human Genetics, University of Warwick, September 2010.
80. National Institute for Health and Clinical Excellence. Identification and management of familial hypercholesterolaemia. Implementing NICE guidance: costing report. London: National Institute for Health and Clinical Excellence; 2009. URL: http://guidance.nice.org.uk/CG71/CostingReport/pdf/English (accessed April 2011).
81. Koivisto PV, Koivisto UM, Miettinen TA, Kontula K. Diagnosis of heterozygous familial hypercholesterolemia. DNA analysis complements clinical examination and analysis of serum lipid levels. Arterioscler Thromb 1992;12:584-92.
82. Ward AJ, O'Kane M, Nicholls DP, Young IS, Nevin NC, Graham CA. A novel single base deletion in the LDLR gene (211delG): effect on serum lipid profiles and the influence of other genetic polymorphisms in the ACE, APOE and APOB genes. Atherosclerosis 1996;120:83-91.
83. Vergotine J, Thiart R, Kotze MJ. Clinical versus molecular diagnosis of heterozygous familial hypercholesterolaemia in the diverse South African population. S Afr Med J 2001;91:1053-9.
84. Humphries SE, Cranston T, Allen M, Middleton-Price H, Fernandez MC, Senior V, et al. Mutational analysis in UK patients with a clinical diagnosis of familial hypercholesterolaemia: relationship with plasma lipid traits, heart disease risk and utility in relative tracing. J Mol Med 2006;84:203-14.
85. Bourbon M, Alves AC, Medeiros AM, Silva S, Soutar AK. Familial hypercholesterolaemia in Portugal. Atherosclerosis 2008;196:633-42.
86. Marteau T, Senior V, Humphries SE, Bobrow M, Cranston T, Crook MA, et al. Psychological impact of genetic testing for familial hyperecholesterolemia within a previously aware population: a randomized controlled trial. Am J Med Genet 2004;128A:285-93.
87. Whiting P, Rutjes AW, Reitsma JB, Glas AS, Bossuyt PM, Kleijnen J. Sources of variation and bias in studies of diagnostic accuracy: a systematic review. Ann Intern Med 2004;140:189-202.
88. Wright WT, Heggarty SV, Young IS, Nicholls DP, Whittall R, Humphries SE, et al. Multiplex MassARRAY spectrometry (iPLEX) produces a fast and economical test for 56 familial hypercholesterolaemia-causing mutations. Clin Genet 2008;74:463-8.
89. Taylor A, Bayly G, Patel K, Yarram L, Williams M, Hamilton-Shield J, et al. A double heterozygote for familial hypercholesterolaemia and familial defective apolipoprotein B-100. Ann Clin Biochem 2010;47:5-90.
90. Van Der Graaf A, Avis HJ, Kusters DM, Vissers MN, Hutten BA, Defesche JC, et al. Molecular basis of autosomal dominant hypercholesterolemia: assessment in a large cohort of hypercholesterolemic children. Circulation 2011;123:1167-73. DOI: 10.1161/CIRCULATIONAHA.110.979450.
91. Van Maarle MC, Stouthard MEA, Mheen PJM, Klazinga NS, Bonsel GJ. How disturbing is it to be approached for a genetic cascade screening programme for familial hypercholesterolaemia?: psychological impact and screenees' views. Community Genet 2001;4:244-52.
92. Van Maarle MC, Stouthard MEA, Bonsel GJ. Risk perception of participants in a familybased genetic screening program on familial hypercholesterolemia. Am J Med Genet 2003;116A:136-43.
93. Marks D, Thorogood M, Neil SM, Humphries SE, Neil HAW. Cascade screening for familial hypercholesterolaemia: implications of a pilot study for national screening programmes. J Med Screen 2006;13:156-9.
94. Will CM, Armstrong D, Marteau TM. Genetic unexceptionalism: clinician accounts of genetic testing for familial hypercholesterolaemia. Soc Sci Med 2010;71:910-17.
95. Alonso R, Mata N, Castillo S, Fuentes F, Saenz P, Muniz O, et al. Cardiovascular disease in familial hypercholesterolaemia: influence of low-density lipoprotein receptor mutation type and classic risk factors. Atherosclerosis 2008;200:315-21.
96. Avis HJ, Huijgen R, Hutten BA, Vissers MN, Janssen TH, Kusters DM, et al. Follow-up of children after positive genetic testing in the Dutch national screening program for familial hypercholesterolemia. Atheroscler Suppl 2010;11:180.
97. Poke S, Watts G, Maxwell S, Brameld K, O'Leary P. Familial hypercholesterolaemia (FH) pilot cascade screening project. Twin Res Hum Genet 2009;12:229.
98. Koeijvoets KCMC, Wiegman A, Rodenburg J, Defesche JC, Kastelein JJP, Sijbrands EJG. Effect of low-density lipoprotein receptor mutation on lipoproteins and cardiovascular disease risk: a parent-offspring study. Atherosclerosis 2005;180:93-9.